Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR07

Integrated Health-System Specialty Pharmacy Support in Reducing Financial Toxicity of Oral Oncolytic Therapy

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Tanner Buchanan, Pharmacy Intern, University of Rochester Specialty Pharmacy, Rochester, NY

Co-Authors: Shannon Gowen, PharmD, Clinical Pharmacist, and Jerimiah Moore, PharmD, Clinical Pharmacist, University of Rochester Specialty Pharmacy, Rochester, NY

BACKGROUND: Oral anticancer therapy has become an increasingly popular alternative to traditional cancer regimens. As a result, patients have fewer office visits and less medication complications.1 Although oral therapy is more convenient than intravenous therapy, oral medications come with significant financial barriers, which can limit patient access to, and affect the success of, these regimens.1,2 In 2019, pharmacists from the University of Chicago Medical Center published an article in the Journal of Managed Care & Specialty Pharmacy that drew attention to the increasing need for an oncology specialty pharmacy to assist with reduced financial toxicity, by securing copay assistance for patients with cancer.3 They reported the results of their study showing that of 75 patients who received financial assistance, the cost-savings ranged from $5 to $13,138 per prescription claim.3 The high cost burden of oral anticancer medications may result in limited access to therapies, delays in starting treatment, and therapy abandonment.1

OBJECTIVES: To determine the total financial support obtained by University of Rochester Specialty Pharmacy to help relieve patients from financial toxicity associated with oral oncolytic medications, and to determine the percentage of patients receiving copay assistance support, including independent foundations, manufacturer copay cards, and social work funding.

METHOD: This retrospective quality improvement project was granted Institutional Review Board exemption. We reviewed prescription claim data for patients who were prescribed an oral oncolytic through the University of Rochester Wilmot Cancer Institute between July 20, 2020, and July 20, 2021, and filled at our specialty pharmacy. The data were analyzed using descriptive statistics.

RESULTS: Over a 1-year period, a total of 12,310 prescription claims were reviewed for 1746 patients who filled an oral oncolytic through our specialty pharmacy. Of these patients, 932 (53.4%) patients received financial assistance, including 25% of patients who used copay assistance from independent foundation grants, 11.2% who used manufacturer copay cards/vouchers, and 17.2% who received financial support through internal social work funding. After optimizing New York State Epic enrollment, our specialty pharmacy patients received $4,403,513.73 in financial assistance, including $2,704,845.41 that was obtained either from independent grants (38.5%), manufacturer copay card/vouchers (41.8%), or the University of Rochester internal social work funding (19.7%). Before financial assistance was obtained, the average patient copay for foundation/grant, copay card, and social work was $328.65, $1730.70, and $807.05, respectively. After financial assistance was obtained through this project, the average patient copay was $0.80, $46.48, and $96.23, respectively.

CONCLUSION: These relatively low copays with our financial assistance program for high-cost oral anticancer therapy highlight the value that an integrated health-system specialty pharmacy has in the care of patients with cancer when financial assistance is obtained.

  1. Zullig LL, Wolf S, Vlastelica L, et al. The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm. 2017;23:407-411.
  2. Niccolai JL, Roman DL, Julius JM, Nadour RW. Potential obstacles in the acquisition of oral anticancer medications. J Oncol Pract. 2017;13:e29-e36.
  3. Farano JL, Kandah HM. Targeting financial toxicity in oncology specialty pharmacy at a large tertiary academic medical center. J Manag Care Spec Pharm. 2019;25:765-769.
Related Items
Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: